Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia

Human Psychopharmacology

Volumn 24, Issue 7, 2009, Pages 565-573

  Kim, Sung Wan ^a   Shin, Il Seon ^a,b   Kim, Jae Min ^a   Lee, Seung Hyun ^c   Lee, Yo Han ^c   Yang, Su Jin ^a   Yoon, Jin Sang ^a,b  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

^c St John Hospital   (South Korea)

Author keywords

Cognitive function; Hyperprolactinemia; Insight; Long acting injectable risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; OLANZAPINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADJUVANT THERAPY; ADULT; AKATHISIA; AMENORRHEA; ARTICLE; ATTENTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; INJECTION SITE PAIN; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PARKINSONISM; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; SKIN TINGLING; SOCIAL INTERACTION; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; VERBAL MEMORY; VISUOMOTOR COORDINATION; WEIGHT GAIN; WISCONSIN CARD SORTING TEST;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; REACTION TIME; RISPERIDONE; SCHIZOPHRENIA; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72849146000     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1057     Document Type: Article

References (43)

1. Addington D, Addington J, Schissel B. 1990. A depression rating scale for schizophrenics. Schizophr Res 3: 247-251.
2. Amador XF, Flaum M, Andreasen NC, et al. 1994. Awareness of illness in schizophrenia, schizoaffective and mood disorders. Arch Gen Psychiatry 51: 826-836. (Pubitemid 24313308)
3. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (4th edn). American Psychiatric Press Inc: Washington, DC.
4. Bai YM, Chen TT, Lin WK, et al. 2007a. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection. J Clin Psychopharmacol 27: 306-308. (Pubitemid 46763318)
5. Bai YM, Chen TT, Lin WK, et al. 2007b. Reply to comments by Dr Peng et al. for "Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection". J Clin Psychopharmacol 28: 727-728.
6. Barnes TR. 1989. A rating scale for drug induced akathisia. Br J Psychiatry 154: 672-676.
7. Beck AT, Ward CH, Mendelson M, et al. 1961. An inventory of measuring depression. Arch Gen Psychiatry 4: 53-63.
8. Benton AL, Hamscher K. 1978. Multilingual Aphasia Examination Manual, Revised. University of Iowa: Iowa City.
9. Chue P, Eerdekens M, Augustyns I, et al. 2005. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15: 111-117. (Pubitemid 39574406)
10. Curtis VA, Katsafouros K, Möller HJ, et al. 2008. Long-acting risperidone improves negative symptoms in stable psychotic patients. J Psychopharmacol 22: 254-261. (Pubitemid 351847446)
11. Eerdekens M, Van Hove I, Remmerie B, et al. 2004. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70: 91-100. (Pubitemid 38916632)
12. Gharabawi GM, Lasser RA, Bossie CA, et al. 2006. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int Clin Psychopharmacol 21: 233-240.
13. Goldberg TE, Goldman RS, Burdick KE, et al. 2007. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64: 1115-1122.
14. Guy W. 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare: Washington, DC; 534-537.
15. Ha KS, Kwon JS, Lyoo IK, et al. 2002. Development and standardization process, and factor analysis of the computerized cognitive function test system for Korea adults. J Korean Neuropsychiatr Assoc 41: 551-562.
16. Haddad PM, Sharma SG. 2007. Adverse effect of atypical antipsychotics: differential risk and clinical implications. CNS drugs 21: 911-936. (Pubitemid 47557106)
17. Hahn HM, Yum TH, Shin YW, et al. 1986. Standardization study of beck depression inventory in Korea. J Korean Neuropsychiatr Assoc 25: 487-502.
18. Harvey PD, Meltzer H, Simpson GM, et al. 2004. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res 66: 101-113. (Pubitemid 38041108)
19. Harvey PD, White L, Parrella M, et al. 1995. The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. Br J Psychiatry 166: 630-633.
20. Heaton RK, Chelune GJ, Talley JL, et al. 1993.Wisconsin Card Sorting Test Manual. Psychological Assessment Resources: Odessa, FL.
21. Hogan TP, Awad AG, Eastwood R. 1983. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13: 177-183. (Pubitemid 13132147)
22. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13: 261-276. (Pubitemid 18039085)
23. Keefe RS, Seidman LJ, Christensen BK, et al. 2006. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 59: 97-105.
24. Keefe RS, Sweeney JA, Gu H, et al. 2007. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1061-1071. (Pubitemid 47121395)
25. Kim SW, Shin IS, Kim JM, et al. 2006a. Association between attitude toward medication and neurocognitive function in schizophrenia. Clin Neuropharmacol 29: 197-205.
26. Kim SW, Kim SJ, Yoon BH, et al. 2006b. Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res 144: 57-63.
27. Kim SW, Yoon JS, Choi SK. 2006c. Survey of medication adherence in patients with schizophrenia - Korean ADHES data. Hum Psychopharmacol 21: 533-537.
28. Kim SW, Shin IS, Kim JM, et al. 2007a. A validation study of the Korean version of subjective well-being under neuroleptic treatment scale - short form. Korean J Psychopharmacol 18: 221-230.
29. Kim SW, Shin IS, Kim JM, et al. 2007b. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31: 1504-1509. (Pubitemid 47307407)
30. Kim SW, Shin IS, Kim JM, et al. 2009. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol (Epub ahead of print).
31. Kim YK, Won SD, Lee KM, et al. 2005. A study on the reliability and validity of the Korean version of the Calgary depression scale for schizophrenia (K-CDSS). J Korean Neuropsychiatr Assoc 44: 446-455.
32. Kwon JS, Lyoo IK, Hong KS, et al. 2002. Development and standardization of the computerized memory assessment for Korean adults. J Korean Neuropsychiatr Assoc 41: 347-358.
33. Lezak MD. 1995. Neuropsychological Assessment (3rd edn). Oxford University Press: New York, NY.
34. Lin KM, Poland RE, Lau JK, et al. 1988. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 8: 195-201.
35. Mohamed S, Paulsen JS, O'Leary D, et al. 1999. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry 56: 749-754. (Pubitemid 29357737)
36. Möller HJ. 2006. Long-acting risperidone: focus on safety. Clin Ther 28: 633-651.
37. Naber D, Moritz S, Lambert M, et al. 2001. Improvement of schizophrenic patients' subjective wellbeing under atypical antipsychotic drugs. Schizophr Res 50: 79-88. (Pubitemid 32510889)
38. Rey A. 1964. L'examen clinique en psychologie. Presses Universitaires de France: Paris, France.
39. Rossell SL, Coakes J, Shapleske J, et al. 2003. Insight: its relationship with cognitive function, brain volume and symptoms in schizophrenia. Psychol Med 33: 111-119. (Pubitemid 36113406)
40. Simpson GM, Angus JWS. 1970. A rating scale for extrapyramidal side effect. Acta Psychiatr Scand 212(suppl): 11-19.
41. Woodward ND, Purdon SE, Meltzer HY, et al. 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 23: 1-16.
42. Yi JS, Ahn YM, Shin HK, et al. 2001. Reliability and validity of the Korean version of the positive and negative syndrome scale. J Korean Neuropsychiatr Assoc 40: 1090-1105.
43. Yoon BH, Bahk WM, Lee KU, et al. 2005. Psychometric properties of Korean version of drug attitude inventory (KDAI-10). Korean J Psychopharmacol 16: 480-487.